You can buy or sell AUPH and other stocks, options, ETFs, and crypto commission-free!
Aurinia Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Victoria, British Columbia
52 Week High
52 Week Low
Seeking AlphaMar 19
Aurinia Pharmaceuticals, Inc. (AUPH) CEO Dr. Richard Glickman on Q4 2018 Results - Earnings Call Transcript
Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) Q4 2018 Results Earnings Conference Call March 19, 2019 4:30 PM ET Company Participants Dr. Glenn Schulman - Investor Relations Dr. Richard Glickman - Chief Executive Officer Dennis Bourgeault - Chief Financial Officer Neil Solomons - Chief Medical Officer Conference Call Participants Ed Arce - H. C. Wainwright Joseph Schwartz - Leerink Operator Greetings and welcome to the Aurinia Fourth Quarter and Full Year 2018 Financial Results and Operational Highl...
The Motley FoolMar 19
Aurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Q4 2018 Earnings Conference Call March 19, 2019, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Greetings and welcome to the Aurinia fourth quarter and full year 2018 financial results and operational highlights conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assista...
Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars. 2018 and Recent Highlights Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for claims which have the potential to cover voclosporin’s method of use and dosing protocol for lupus nephriti...
-$0.14 per share
-$0.17 per share